Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
Winship Cancer Institute of Emory University- Site Number : 8400010, Atlanta, Georgia University of Illinois-Chicago - College of Medicine- Site Number : 8400007, Chicago, Illinois University of Michigan Health System - Ann Arbor- Site Number : 8400004, Ann Arbor, Michigan Roswell Park Cancer Institute- Site Number : 8400008, Buffalo, New York The Ohio State University- Site Number : 8400012, Columbus, Ohio Australia
Investigational Site Number : 0360006, Wollongong, New South Wales Investigational Site Number : 0360002, Melbourne, Victoria Investigational Site Number : 0360001, Richmond, Victoria France
Investigational Site Number : 2500003, Paris, Washington Investigational Site Number : 2500002, Lille Investigational Site Number : 2500001, Nantes Investigational Site Number : 2500004, Paris Germany
Investigational Site Number : 2760006, Frankfurt Investigational Site Number : 2760008, Lübeck Greece
Investigational Site Number : 3000002, Athens Investigational Site Number : 3000001, Athens Israel
Investigational Site Number : 3760002, Jerusalem Investigational Site Number : 3760003, Ramat Gan Investigational Site Number : 3760001, Tel Aviv Italy
Investigational Site Number : 3800001, Meldola, Reggio Emilia Norway
Investigational Site Number : 5780001, Oslo Portugal
Investigational Site Number : 6200001, Coimbra Investigational Site Number : 6200002, Porto Puerto Rico
Puerto Rico Medical Research Center- Site Number : 8400005, Hato Rey, Puerto Rico South Korea
Investigational Site Number : 4100001, Seoul, Seoul-teukbyeolsi Investigational Site Number : 4100004, Seoul, Seoul-teukbyeolsi Investigational Site Number : 4100002, Seoul, Seoul-teukbyeolsi Investigational Site Number : 4100003, Seoul, Seoul-teukbyeolsi